Back

Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial

28 August 2023 (11:05 - 11:15)
Organised by: Logo
Congress Presentation Part of: Diabetes and the heart Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Ofer Kobo

Hillel Yaffe Medical Center, Hadera (Israel)

5 More presentations in this session

Presentation thumbnail
ZNF259 rs964184 genetic variant is associated with metabolic syndrome in a Portuguese population
Doctor D. Sa (Funchal, PT)
Abstract Slides Video
Presentation thumbnail
Effect of exercise in incident atrial fibrillation among diabetes mellitus with different diabetes duration
Miss J. Choi (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Metabolic disorders predict future impairment of kidney function in the Japanese general population
Doctor F. Kin (Hamamatsu, JP)
Abstract Slides Video
Presentation thumbnail
Outcomes of diabetic patients with acute coronary syndromes treated with aspirin in primary prevention
Doctor H. Costa (Faro, PT)
Abstract Slides Video
Presentation thumbnail
Myocardial performance index improves prediction of major adverse cardiovascular events and heart failure in type 1 and type 2 diabetes without known heart disease: Thousand&1 and Thousand&2 study
Doctor H. Bahrami (Herlev, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes and the heart
Video

The Event

Event poster

ESC Congress 2023

28 August 2023 11:05 CET
You may be interested in
thumbnail
Congress Session
Late-Breaking Clinical Science: cardiometabolic medicine
thumbnail
Congress Presentation
Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources